• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    What Science-Backed Subscription Health Programs Measure Differently

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples
    Get the next $MED alert in real time by email
    • The weight loss and weight management market was valued at $31.07 billion in 2025 
    • A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimed
    • DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scale
    • Study completion rates carry significant weight in how research findings should be interpreted

    BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically studied," "science-backed," "proven," and "evidence-based" appear across a wide spectrum of programs, from programs with published randomized controlled trials to those with ingredient-level pilot data. However, many of those terms are used without specifying what was measured, by whom, or with what tools. The difference between those two categories is substantial, and it only becomes visible when consumers know what to look for. OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, has built its research portfolio on peer-reviewed randomized controlled trials with findings verified through clinical gold-standard body composition measurement.

    "The clinical evidence behind our program is substantial because it documents real outcomes in real participants," said Satya Jonnalagadda, PhD, MBA, RD, Vice President of Scientific & Clinical Affairs at OPTAVIA. "When people can find that research easily, it builds trust and credibility while also changing the conversation about what a science-backed program actually looks like."

    KEY FACTS

    • 98% lean mass retained by individuals on the OPTAVIA Optimal Weight 5 & 1 Plan® at 16 weeks, per a randomized controlled trial (Arterburn LM, et al., 2019)
    • 10 times more weight and 17 times more fat lost by coach-supported clients vs. the self-directed control group in the same study (Arterburn LM, et al., 2019)



    Claims Made in a $31 Billion Industry

    According to Research and Markets, the weight loss and diet management market was valued at $31.07 billion in 2025 and is expected to surpass $45 billion by 2030. As the market expands, so do its claims. Weight loss programs operate in a market regulated by both the FTC and the FDA, but within that framework, marketing terms like 'clinically studied,' 'science-backed,' and 'evidence-based' do not carry standardized evidentiary definitions. A program can apply those terms to a full randomized controlled trial or to a single ingredient-level pilot study, and both uses may be technically permissible depending on how the claim is structured. The terms don't require specifics on what was measured, how it was measured, or if the measurement tool could capture the claimed outcome.

    Scale weight is one of the most common reporting metrics for weight loss programs because it is easy to collect, but it does not distinguish between fat lost and muscle lost, and it does not capture what is happening to visceral fat stored around organs. Two programs can report identical pounds lost while producing meaningfully different effects on the body's metabolic composition. The difference only becomes visible when measurement goes deeper than a scale.

    Dual-energy X-ray absorptiometry (DXA) scanning is the clinical gold standard for body composition assessment. This is because DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scale. A 16-week randomized controlled OPTAVIA trial published in Obesity Science & Practice used DXA throughout to track body composition changes in 198 participants (Arterburn LM, et al., 2019). This methodological choice makes the reported outcomes verifiable in a way that self-reported data is not.

    What a 92.3% Completion Rate Actually Signals

    Study completion rates carry significant weight in how research findings should be interpreted. In weight loss research, high completion rates add credibility to published outcomes because they indicate the study reflects a broad range of participant experiences.

    The trial published in Obesity Science & Practice reported a 92.3% completion rate across 198 enrolled participants over 16 weeks (Arterburn LM, et al., 2019). The published outcomes of this study included 98% lean mass retained and a 14% reduction in visceral fat. High completion rates like the one in this study indicate results reflect a broad range of participant experiences, not only those most likely to succeed.

    Subscription health programs will continue to proliferate, and so will the outcome language that accompanies them. Trials with high completion rates, DXA-verified body composition outcomes, and correlation between coaching engagement and results represent a documentable standard of evidence, one that scale weight reporting and self-reported data cannot replicate. For consumers evaluating programs on those terms, the methodological record provides a reliable signal.

    FAQ

    Q: What does "clinically studied" actually mean on a weight loss program's marketing?

    A: It can apply to anything from a full randomized controlled trial to a single ingredient tested in isolation. 

    Q: How do I find a weight loss program with genuine peer-reviewed research behind it?

    A: Look for programs that publish findings in peer-reviewed journals using randomized controlled trials, not observational data or ingredient-level studies. Check whether body composition outcomes are reported alongside total weight lost, what measurement tools were used, and what the study completion rate was. A Scientific Advisory Board composed of externally credentialed researchers is a further indicator of independent scientific oversight.

    Q: Why does body composition measurement matter more than scale weight in weight loss research?

    A: Scale weight does not distinguish between fat loss and lean mass loss, and it does not capture changes in visceral fat stored around organs. Programs that use DXA scanning throughout a study are measuring outcomes that scale weight alone can't verify.

    Q: What does a high study completion rate indicate about a weight loss program's research?

    A: High completion rates add credibility to published outcomes because they indicate results that reflect a broad range of participant experiences, not only those most likely to succeed regardless of the intervention. 

    * OPTAVIA recommends that you contact your healthcare provider before starting and throughout your weight loss journey. Average weight loss on the Optimal Weight 5 & 1 Plan® is 12 pounds. Clients are in weight loss, on average, for 12 weeks.

    * Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019.

    https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the OPTAVIA® 5 & 1 Plan® experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Those on the Optimal Weight 5&1 Plan® with support of an OPTAVIA® Coach successfully lost 10x more weight and 17x more fat than those who tried to lose weight on their own.

    About Medifast

    Medifast (NYSE:MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to address the challenges of metabolic dysfunction, the company's holistic approach integrates personalized plans, scientifically developed products and a framework for sustainable habit creation — all supported by a dedicated network of independent coaches.

    Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through targeted metabolic reset. Research demonstrates that the company's comprehensive system activates strong and targeted fat burning to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle integrity.

    Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. For more information, visit www.MedifastInc.com.



    Sarah Evans
    Head of PR, Zen Media
    sarah@zenmedia.com

    Primary Logo

    Get the next $MED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED

    DatePrice TargetRatingAnalyst
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    10/13/2023$82.00Equal-Weight
    Stephens
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    11/8/2021$395.00 → $349.00Buy
    DA Davidson
    More analyst ratings

    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schlackman Scott bought $62,950 worth of shares (5,000 units at $12.59), increasing direct ownership by 20% to 30,549 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/12/26 7:10:46 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    What Science-Backed Subscription Health Programs Measure Differently

    The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimedDXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scaleStudy completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically st

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

    Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progressSleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stallThe coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain BALTIMORE, MD, June

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    SEC Filings

    View All

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    6/1/26 8:59:46 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    5/26/26 4:26:14 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC

    SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)

    5/14/26 5:05:23 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rose Jeffrey Matthew was granted 18,419 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:34:17 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Kiai Parsa was granted 19,317 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Thomas Andrea B was granted 11,680 shares, increasing direct ownership by 49% to 35,697 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:01 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Financials

    Live finance-specific insights

    View All

    Medifast Announces First Quarter 2026 Financial Results

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership

    5/4/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or

    4/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385

    2/17/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by MEDIFAST INC (Amendment)

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    2/13/24 10:36:09 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology